Antiviral Could Elevate Biotech Company to New Heights

With its ongoing expansion and development of its diverse and promising product pipeline... [Crystal Clear News](2FZW1haWw9dHJpc3RyYW1iYWxkd2luOTFAZ21haWwuY29tJmFpZD00JnB0bj1DQ04%3D/ea0acff410c0067590103b709c1db443h?x-ew-link-index=1) [hidden]( IN PARTNERSHIP WITH NANOVIRICIDES, INC 3D/d15d236baca43fbe68a967767e507d98h?x-ew-link-index=1 [There is no denying that the world is changing… viruses are becoming more rampant. But an exciting NYSE small-cap company is ahead of the problem with an innovative answer.](3D/d15d236baca43fbe68a967767e507d98h?x-ew-link-index=2) With its ongoing expansion and development of its diverse and promising product pipeline, this emerging biotech company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space. Lead Candidate NV-387 (Drug Product NV-CoV-2) Could Revolutionize Antiviral Treatment Just as Antibiotics Did Against Bacteria! NV-387 is aimed to treat RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections. The company has been able to develop NV-387 already for oral administration, as well as for injectable and inhalation formulations to enable many modes of use. This comparison of features of nanoviricides technology platform and, in particular, NV-387, with the revolutionary antibiotics development against bacteria argues that this company is now on a solid footing to revolutionize treatment of antiviral infections! Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field, enabling the company to anticipate that nanoviricide drugs could have many decades long of “life of service.” No matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective. Thus NV-387 and other antiviral drugs designed on the nanoviricides platform can be expected to have a long duration of effective usability against the target viruses, reaching into several decades, similar to antibiotics, but in stark contrast with current antiviral approaches. They could be a highly desirable drug globally. It would enable treatment of patient as soon as they present to the physician with a viral disease without waiting for a test for identifying which viral infection it is! [See how the company has already demonstrated that NV-387 is highly effective in preclinical studies against lethal RSV infection as well as against lethal Smallpox-like virus infections.](3D/d15d236baca43fbe68a967767e507d98h?x-ew-link-index=3) Your email address is on this list as a result of a subscription, information request, competition, or other correspondence you may have had with us in the past. If you would like to be removed from our list, check the email address this newsletter was sent to and use the following link: [Unsubscribe](3D%3D/3c2961563e4015984477ed78a23dc684h). Privacy policy available [here](3D%3D/f38f8d2a6ce2b1853c11f0959fac1493h?x-ew-link-index=1). [CrystalClearNews.com](3D/3bfc287b895767e73d201686725cf844h?x-ew-link-index=1) 4023Kennett Pike Wilmington, Delaware, 19807 United States of America This message is a PAID ADVERTISEMENT for NanoViricides, Inc (NYSE American: NNVC) from Interactive Offers. CrystalClearNews.com receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $1870. Other than the compensation received for this advertisement sent to subscribers, CrystalClearNews.com and its principals are not affiliated with either NanoViricides, Inc. (NYSE American: NNVC) or Interactive Offers. CrystalClearNews.com and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither CrystalClearNews.com nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from CrystalClearNews.com to buy or sell any security. CrystalClearNews.com has not evaluated the accuracy of any claims made in this advertisement. CrystalClearNews.com recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results.